EBS - Emergent COVID-19 immunoglobulin therapy fails in phase 3

An experimental COVID-19 treatment from Emergent BioSolutions (EBS) failed in a phase 3 trial.Emergent's experimental SARS-CoV-2 immunoglobulin  therapy (COVID-HIG), which was combined with Gilead's (GILD) Veklury (remdesivir), did not provide any benefit when compared to standard of care plus placebo.Laura Saward, SVP and therapeutics business unit head at Emergent, said in a statement that using the COVID-HIG therapy earlier in the disease course may provide an impact on patients, and will continue to examine the treatment in other trials.The trial was sponsored and funded by the National Institute of Allergy and Infectious Diseases.Earlier this week, Emergent made headlines after it was reported employee error led to a manufacturing mixup that ruined 15M doses of Johnson & Johnson's COVID-19 vaccine.

For further details see:

Emergent COVID-19 immunoglobulin therapy fails in phase 3